Extract

For a full list of author institutions, see Appendix S1.

Funding sources: none.

Conflicts of interest: A.P.V. is a consultant for Bailleul (2017), GSK (2017), Janssen (2018) and Novartis (2018); D.J. is a consultant for AbbVie, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sandoz; P.G. is a consultant for AbbVie and Novartis and has provided lectures for AbbVie, Convatec, Cicaplus and Brothier; J.D. is a consultant for Novartis, Janssen, AbbVie, Leo Pharma and Sanofi.

C.L. and A.P.V. contributed equally as first authors; D.J. and P.G. contributed equally as last authors.

Dear Editor, Garg et al.1 recently highlighted that cannabis use was more common in patients with hidradenitis suppurativa (HS) (1·2%) compared with the general population (0·4%). However, the reasons why patients with HS are more prone to cannabis abuse are unknown: one can hypothesize that cannabis could be a trigger of the disease or a consequence of the chronic pain associated with HS. Our aims were to determine the prevalence and reasons for cannabis use in patients with HS.

You do not currently have access to this article.